PRL3-zumab for neovascular (wet) age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, randomized, placebo-controlled Phase 1/2 study at the National University Hospital, Singapore, enrolling patients with nAMD who failed at least two standard-of-care intravitreal therapies. Participants are randomized to receive PRL3-zumab 3 mg/kg, PRL3-zumab 6 mg/kg, or placebo (normal saline) intravenously every two weeks for three doses, followed by approximately 20 weeks of monitoring. Safety monitoring includes ocular and systemic adverse event surveillance using CTCAE v5, physical exams, vitals, and laboratory testing, with ocular exams at each dosing visit and every 4 weeks thereafter. Efficacy and response assessments are performed at regular intervals through week 24 post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with Neovascular Age-related Macular Degeneration (nAMD).
2. Willing to provide written informed consent for the study.
3. Patients undergoing intravitreal treatment having failed at least two Standard-of care treatments and be receiving ongoing intravitreal treatment at intervals of ≤ 8 weeks including Ranibizumab, Aflibercept, or Faricimab.
4. Participants receiving intravitreal treatment at screening must complete a wash-out period before enrolment. This wash-out period should be calculated based on five half-lives of the specific intravitreal treatment the participant is receiving.

   Below is the washing out period for some standard of care treatments.
   1. Ranibizumab (half-life: 9 days) requires a wash-out period of 45 days (7 weeks)
   2. Aflibercept (half-life: 11 days) requires a wash-out period of 55 days (8 weeks)
   3. Faricimab (half-life: 7.5 days) requires a wash-out period of 37.5 days (5 weeks)
   4. Bevacizumab (half-life: 6 days) requires a wash-out period of 30 days (4weeks)
5. Subfoveal CNV or juxtafoveal/extrafoveal CNV with a subfoveal component related to the CNV activity identified by FFA or OCT (where CNV activity is defined as showing evidence of subretinal fluid, subretinal hyperreflective material, or leakage).
6. BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
7. Decrease in BCVA determined to be primarily the result of nAMD or DR/DME in the study eye.
8. Presence of pigment epithelium detachment (PED), intraretinal fluid (IRF) and/or subretinal fluid (SRF) affecting the central subfield of the study eye on OCT.
9. Adequate organ (liver and renal) and hematological functions as evidenced by the laboratory results obtained within 7 days of treatment which are within the normal range for the study population, or with abnormalities deemed not clinically significant by the investigators.

Exclusion Criteria:

1. Scar, fibrosis, atrophy, or retinal pigment epithelial tears involving the central fovea in the study eye.
2. Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with antiglaucoma medication) in the study eye.
3. History of idiopathic or autoimmune uveitis in the study eye.
4. Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
5. Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
6. Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg).
7. Patient is receiving systemic glucocorticoids (only if higher than 10mg or equivalent of prednisolone daily) or other immunosuppressive treatment for autoimmune disease or any other medical condition.

Where it's running

• NUHS Department of Ophthalmology
  Singapore, Singapore Recruiting

Study contacts

• Study coordinator: Dr Koon Hwee Ang (David)
• Email: ang.koonhwee@intra-immusg.com
• Phone: +65 65869661

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABP 938 8 mg vs EYLEA® HD (aflibercept) in neovascular AMD

  This trial tests whether ABP 938 8 mg works as well as aflibercept 8 mg in people with neovascular AMD.

  Recruiting at 81 sites Phase 3 Amgen · Fullerton, California and 80 other locations · NCT07614776

• PRL3-zumab treatment for advanced solid cancers

  This Phase II/III study will test whether IV PRL3-zumab (6 mg/kg) given every two weeks can control tumors and is safe in adults with advanced solid cancers.

  Recruiting at 4 sites Phase 2/3 Intra-IMMUSG Pte Ltd · Kota Bharu and 3 other locations · NCT07290088

• IBI302 treatment for neovascular age-related macular degeneration

  This trial will try intravitreal 8 mg IBI302 injections to see if they help people aged 50 and older with active neovascular (wet) AMD.

  Recruiting Phase 2 Innovent Biologics Technology Limited (Shanghai R&D Center) · Shanghai, Shanghai Municipality · NCT07275840

• LX111 gene therapy for neovascular (wet) age-related macular degeneration

  This will test a single eye injection of LX111 gene therapy in people 50 and older with active wet AMD to see if it is safe and helps maintain or improve vision.

  Recruiting Early Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07053358

• Surabgene Lomparvovec to reduce injections and preserve vision in adults with wet AMD

  This study will test whether a single subretinal dose of Surabgene Lomparvovec can reduce the need for repeated eye injections and help preserve vision in adults 50 and older with previously treated neovascular (wet) AMD compared with standard ranibizumab care.

  Recruiting at 138 sites Phase 3 AbbVie · Mesa, Arizona and 137 other locations · NCT07007065

• Effects of Faricimab on kidney function in diabetic patients

  This study is testing if a new eye injection called Faricimab can help improve kidney function in people with diabetes compared to a standard treatment.

  Recruiting University Hospital, Alexandroupolis · Alexandroupoli, Evros and 1 other locations · NCT06929507

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.